UTHR
United Therapeutics Corporation
$513.12
-1.51%
2026-08-21
About United Therapeutics Corporation
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
Key Fundamentals
P/E Ratio
17.89
Forward P/E
16.56
EPS (TTM)
$27.93
ROE
19.3%
Revenue Growth (YoY)
-1.9%
Profit Margin
41.6%
Price/Book
3.33
Beta
0.56
Market Cap
$21.43B
Avg Volume (10D)
608K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$574.00
60D Low
$490.80
Avg Volume
473K
Latest Close
$513.12
Get breakout alerts for UTHR
Sign up for Breakout Scanner to receive daily notifications when UTHR triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
United Therapeutics Corporation (UTHR) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors UTHR daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. UTHR operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry. Data is provided for informational purposes only and does not constitute financial advice.